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SHORT COMMUNICATION
CA-125 is not a useful marker in metastatic breast cancer
M.J. Seckl, G.J.S. Rustin & R.C. Coombes
Department ofMedical Oncology, CRC Laboratories, Charing Cross Hospital, Fulham Palace Road, London W6 8RF, UK.
Several tumour markers are known to be elevated in patients
with breast cancer. A recent paper has suggested that CA-125
may be a useful marker in patients with advanced breast
cancer (Perey et al., 1990). We and others have previously
shown that CA-125 is indeed helpful in predicting disease
response to chemotherapy and detecting early relapse for
ovarian cancer (Bast et al., 1983; Rustin et al., 1992). We
now report our experience with CA-125 in 36 patients with
metastatic breast cancer.
Methods
Thirty-six patients with advanced breast cancer enrolled
between 1988 and 1991 had serial CA-125 measurements
during therapy for their disease. All the patients had received
some form of prior treatment. Response to therapy was
assessed by clinical palpation, chest X-ray (CXR), ultrasound
(U/S) of the liver, CT scanning where CXR and U/S pro-
vided inadequate information, liver function tests (LFT),
bone scanning and limited skeletal surveys. The clinical
course was scored as responsive disease (RD), stable disease
(SD) or progressive disease according to the UICC/WHO
criteria for clinical evaluation (Miller et al., 1981).
Responsive disease included both partial and complete
responses. The patients were reviewed clinically at each atten-
dance for chemotherapy or otherwise monthly with a full
blood count, LFT and CA-125. The minimum follow-up
period was 4 months with a mean of 14 months. Non clinical
assessable disease was evaluated every 2-3 months.
Serum was stored at between -20 and - 80'C prior to
assay. The CA-125 was quantified using an immunoradio-
metric assay (Abbott CA-125 kit). A cut off level of >35 iu
ml-' was identified as an abnormal result (Bast et al., 1983).
The CA-125 was deemed to be in concordance with PD if
there was a >25% increase in the CA-125 value above the
base line reading which persisted in a further sample a month
later. Similarly a >25% decrease in CA-125 persisting for a
month was deemed to be in concordance with RD. Patients
with a normal CA-125 at entry into the study continued to
have CA-125 measurements and were all eligible if their
CA-125 levels agreed with disease activity at a later date.
Results
The average number of CA-125 estimates per patient was 12.
Of the 36 patients 23 (64%) had a raised CA-125 at entry
although all had metastatic disease. Of the 35 episodes of PD
that occurred in the study period 21 had a > 25% rise in
CA-125 giving a sensitivity of 60% (Table I). However only
13 of these actually had a rising CA-125 prior to clinical
detection of their relapse. There were 29 episodes of RD,
55% of which showed a >25% fall in the CA-125, but only
41% had a fall in CA-125 prior to detection of clinical
improvement. The CA-125 falsely predicted PD in 32% of
episodes and falsely predicted RD in 29% of episodes. Only
three of the 13 patients that had more than one episode of
disease change during the study period had CA-125 values
that were in concordance with all of their disease course.
Thus ten patients had CA-125 values that were useful only
some of the time. A major problem encountered with enter-
preting the CA-125 changes was the high degree of variation
in levels with time even when little change had occurred in
disease status. An example of this is shown in Figure 1. This
was one of the reasons why CA-125 and SD were in concord-
ance in only 20% of the ten episodes seen.
None of the patients in the study had any significant past
medical histories. All had normal renal function and those
with abnormal LFTs had known liver metastases (nine of 12
patients). In the latter cases the CA-125 did not rise despite
deteriorating LFTs.
Table I Concordance and false positive rate ofCA-125 with disease course in metastatic breast
cancer
CA-125 False
Number of concordance No CA-125 CA-125 preceded positive
episodes (sensitivity) concordance clinical change rate
PDa 35 21 (60%) 14 (40%) 13 (37%) 32%
44.7 73.9%d 26 55%d 14-84 dayse
42 daysf
RDb 29 16 (55%) 13 (45%) 12 (41%) 29%
38.4-71%d 29-61.5%d 14-72 dayse
28 daysf
SDc 10 2 (20%) 8 (80%) -
36.7-50.7% 49-96%
Total 74 39 (53%) 35 (47%)
aPD= progressive disease; bRD = responsive disease; CSD static disease; d95% binomial
confidence interval calculated using incomplete beta function (Blyth, 1986). 'Range; fMedian.
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Figure 1 Fluctuating CA-125 values with disease course in a
patient with metastatic breast cancer.
Discussion
Tumour markers must fulfill certain criteria if they are to be
useful in clinical practice (Beastall et al., 1991). In metastatic
cancer these include sufficient sensitivity and specificity to
allow early changes in management which may affect out-
come. In addition tumour markers may also be seen to be
saving money if they avoid unnecessary investigations (Rus-
tin et al., 1992). Previous studies have shown that the CA-
125 may be elevated in 12-18% of patients with advanced
breast cancer (Bast et al., 1983; Kawahara et al., 1986). This
suggested that CA-125 would not be a useful marker of
disease activity. However, Perey et al. looked at 40 metastatic
breast patients, performing three ofmore CA-125 assays over
a period of time and found that 16 (40%) had elevated
CA-125 levels at presentation. Seventeen patients (43%) had
CA-125 levels that correlated with disease activity (PD+
RD + SD). They suggest that CA-125 may be a useful
marker in advanced breast cancer.
We agree that CA-125 is more commonly elevated in
metastatic breast cancer (64%) than previously recognised.
Although the sensitivity of serial CA-125 assays was only
60% for RD and 55% for PD, it preceeded clinical findings
in fewer than 42% ofcases. Furthermore, in 32% of progres-
sive disease episodes, the CA-125 fell or did not rise despite
being elevated (in ovarian cancer CA-125 wrongly predicts
PD in fewer than 10% of cases (Rustin et al., 1992)).
Similarly in 29% of responsive disease episodes the CA-125
actually rose or remained elevated. There is no way of
predicting which patients will have CA-125 values that are in
concordance with their disease activity and the patients who
do have CA-125 measurements which agree with disease
change on one occasion may not agree on the next occassion.
Only three of the 13 patients who had more than one change
in disease status with a concording CA-125, continued to
have a CA-125 which was in concordance with their disease.
These facts clearly show that CA-125 is not a useful
marker of disease activity in metastatic breast cancer and its
continued use in such patients can only be seen as wasting
resources. We conclude that this data does not support the
view expressed by Perey et al. that CA-125 maybe a useful
marker in advanced breast cancer.
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